Get the Stockscreener App
10.13
0.59%
-0.06
After Hours:
10.01
-0.12
-1.18%
Nextcure Inc stock is traded at $10.13, with a volume of 31,539.
It is down -0.59% in the last 24 hours and down -22.08% over the past month.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
See More
Previous Close:
$10.19
Open:
$10.02
24h Volume:
31,539
Relative Volume:
0.91
Market Cap:
$36.07M
Revenue:
-
Net Income/Loss:
$-55.84M
P/E Ratio:
-0.5757
EPS:
-17.5951
Net Cash Flow:
$-49.61M
1W Performance:
+0.50%
1M Performance:
-22.08%
6M Performance:
+77.72%
1Y Performance:
+1,806%
1-Day Range:
$10.01
$10.95
1-Week Range:
$9.205
$10.99
52-Week Range:
$0.224
$15.74
Nextcure Inc Stock (NXTC) Company Profile
Name
Nextcure Inc
Sector
Industry
Phone
240-399-4900
Address
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
10.13 | 36.28M | 0 | -55.84M | -49.61M | -17.60 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Nov-04-22 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| Mar-05-21 | Upgrade | Truist | Hold → Buy |
| Jan-15-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-16-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-13-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-13-20 | Downgrade | SunTrust | Buy → Hold |
| Jun-01-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-01-20 | Downgrade | The Benchmark Company | Buy → Hold |
| May-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Mar-24-20 | Initiated | The Benchmark Company | Buy |
| Mar-02-20 | Initiated | ROTH Capital | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-05-19 | Initiated | Needham | Buy |
| Nov-26-19 | Initiated | BTIG Research | Buy |
| Jul-09-19 | Initiated | BofA/Merrill | Buy |
| Jun-03-19 | Initiated | Morgan Stanley | Overweight |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Nextcure Inc Stock (NXTC) Latest News
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Buy Signal: Is NextCure Inc a defensive stockQuarterly Trade Review & Growth-Oriented Investment Plans - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Aug Action: Is CF Bankshares Incs growth already priced in2026 Chart Watch & Proven Capital Preservation Methods - baoquankhu1.vn
Published on: 2026-03-22 18:56:49 - baoquankhu1.vn
LOW Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
HTH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BKT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Travel Stocks: Is NextCure Inc stock good for income investorsTrade Risk Assessment & AI Forecast Swing Trade Picks - baoquankhu1.vn
NextCure Inc Stock (ISIN: US65343E1082) Faces Analyst Downgrade Amid Biotech Sector Headwinds - AD HOC NEWS
NextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease Treatment - MSN
NextCure Provides Business Update and Reports Full Year 2025 Financial Results - The Manila Times
NextCure Inc reports results for the quarter ended September 30Earnings Summary - TradingView
NextCure 10-K: $0 Revenue, $(19.65) EPS reported - TradingView
NextCure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cancer drug developer NextCure maps 2026 trial milestones and funding runway - Stock Titan
NXTC SEC FilingsNextcure 10-K, 10-Q, 8-K Forms - Stock Titan
NextCure, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
NextCure Inc expected to post a loss of $2.42 a shareEarnings Preview - TradingView
Hedge Fund Bets: Is NextCure Inc stock good for income investorsJuly 2025 Summary & Expert-Curated Trade Recommendations - baoquankhu1.vn
NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday - Defense World
Published on: 2026-02-26 09:55:29 - baoquankhu1.vn
NextCure (NASDAQ:NXTC) Stock Price Down 3.7% – What’s Next? - Defense World
Can NextCure Inc. stock double in next 5 yearsWeekly Investment Report & Technical Entry and Exit Tips - mfd.ru
Squadron funds disclose 9.99% holding in NextCure (NXTC) common stock - Stock Titan
Will The Allstate Corporation stock benefit from green energy trendsIPO Watch & Weekly Return Optimization Alerts - mfd.ru
NXTC Technical Analysis & Stock Price Forecast - Intellectia AI
Is FSLR stock a top pick in earnings seasonMarket Trend Summary & Precise Swing Trade Alerts - mfd.ru
Street Watch: Is NextCure Inc stock showing strong momentumGap Down & Community Verified Trade Signals - baoquankhu1.vn
Cancer index surges 72% as Terns, Olema lead gains - BioWorld MedTech
Aug Catalysts: Is NextCure Inc stock showing strong momentumJuly 2025 Spike Watch & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Fund Flows: What is LanzaTech Global Inc. Equity Warrant s revenue forecastMarket Movement Recap & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
getLinesFromResByArray error: size == 0 - mfd.ru
NextCure provides updates on ADC programs, reports cash position By Investing.com - Investing.com South Africa
NextCure Provides Business Update - citybiz
NextCure Updates ADC Pipeline Progress and Cash Runway - TipRanks
Next Cure Highlights Progress Across ADC Pipeline As Company Extends Cash Runway Into 2027 - Nasdaq
NextCure provides updates on ADC programs, reports cash position - Investing.com
NextCure provides business update - marketscreener.com
NextCure Provides Business Update - GlobeNewswire Inc.
NXTC: SIM0505 and LNCB74 advance in Phase 1, with strong efficacy and key data expected in 2026 - TradingView
Is Concord Medical Services Holdings Limited stock included in top ETFsJuly 2025 Final Week & Fast Entry Momentum Trade Alerts - bollywoodhelpline.com
Market Outlook: What’s the RSI of ON24 Inc. stockJuly 2025 Highlights & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Buyout Rumor: Can NextCure Inc stock deliver 10 annual returnsWeekly Risk Summary & Safe Entry Point Identification - Bộ Nội Vụ
Aug Setups: How liquid is NextCure Inc stockPortfolio Return Summary & AI Forecasted Stock Moves - baoquankhu1.vn
What margin trends mean for NextCure Inc. stock2025 Institutional Moves & Stock Timing and Entry Methods - Улправда
Will NextCure Inc. stock remain a Wall Street favorite2025 Technical Patterns & Weekly Breakout Stock Alerts - ulpravda.ru
Will Banzai International Inc. Equity Warrant stock deliver better than expected guidance - Улправда
Will NextCure Inc. stock maintain growth storyMarket Activity Report & Scalable Portfolio Growth Methods - Улправда
Will NextCure Inc. stock benefit from automation2025 Volume Leaders & AI Optimized Trade Strategies - Улправда
How analysts revise price targets for XYZY stockEarnings Beat & Free Real-Time Volume Trigger Notifications - Улправда
Nextcure Inc Stock (NXTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):